Biotech pops, AI chips heat up, futures slide 📉

🌅 Today's Morning Call

S&P Futures 6,504.75 ▼ -47.25 (-0.72%)	Nasdaq Futures 23,675.00 ▼ -223.00 (-0.93%)	Dow Futures 46,090.00 ▼ -319.00 (-0.69%)
10Y Treasury 4.42% ▲ +0.09%	US Dollar 100.09 ▲ +0.23 (+0.23%)	Bitcoin $66,659 ▼ -$2,114 (-3.07%)

Good morning! Markets are looking to end the week on a softer note, with futures pointing to losses across all major indexes as Treasury yields climb and the dollar flexes its muscle. But it's not all red on the board this Friday. Biotech is delivering some fireworks with an FDA approval sending one small cap into orbit, while Big Pharma notches a win in the respiratory space. Here's your morning rundown.

👀 What to Watch Today

Healthcare is stealing the spotlight in pre-market action. Rocket Pharmaceuticals (RCKT) is up a solid 10% after snagging FDA approval for its gene therapy treating a rare immune disorder in children. This is the kind of binary event that can make or break a biotech stock, and today it's making it. Meanwhile, AstraZeneca (AZN) is catching a bid after announcing its experimental COPD drug tozorakimab hit primary endpoints in two late-stage trials, showing meaningful reductions in flare-ups for chronic lung disease patients.

The tech sector is dealing with a mixed bag of developments. SoftBank (SFTBY) just secured a massive $40 billion loan to double down on its OpenAI investment, signaling continued confidence in the AI arms race despite recent market jitters. Over in the automotive tech space, Volkswagen (VWAGY) and Rivian (RIVN) are clearing a major hurdle in their software collaboration, a partnership that's central to VW's turnaround strategy and could validate Rivian's tech beyond its own vehicle lineup.

On the disappointment front, Japanese lunar startup ispace (IPCEF) is pushing its NASA-backed moon mission all the way to 2030 while cutting staff globally. It's a reality check for the commercial space sector that capital efficiency still matters when the mission timelines stretch and the burn rate climbs.

Do not ignore. The biggest tech story of our time. [ad]

🌏 Overnight Recap

Asian markets closed mixed overnight, with tech stocks taking cues from Wall Street's recent volatility. The big story out of China involves Huawei's latest AI chip, which is reportedly performing well in customer testing and attracting orders from heavyweights like ByteDance and Alibaba (BABA). This development underscores how Chinese tech giants are building their own semiconductor ecosystem in response to U.S. export restrictions, creating a parallel AI infrastructure that could reshape global chip dynamics.

European markets are trading in the red this morning, weighed down by rising bond yields and concerns about economic momentum heading into the second quarter. The stronger dollar isn't helping sentiment for multinational exporters, and energy stocks are feeling pressure as crude prices soften.

Treasury yields are pushing higher across the curve, with the 10-year now sitting at 4.42%, up 9 basis points. The 5-year is climbing even faster, adding 12 basis points to reach 4.09%. This steepening move suggests the market is reassessing the Fed's rate path, and it's putting pressure on growth stocks in pre-market trading. Bitcoin is down over 3% to $66,659, reflecting broader risk-off sentiment as the dollar index climbs above 100.

This simple-proven strategy could be life-changing (free) [ad]

📊 Pre-Market Movers

Rocket Pharmaceuticals (RCKT) is the clear winner in pre-market, surging 10% after the FDA green-lit its gene therapy for a rare childhood immune disorder. This approval opens up a commercial pathway for a treatment addressing a serious unmet medical need, and the market is pricing in meaningful revenue potential. AstraZeneca (AZN) is also moving higher on its positive COPD trial data, adding another potential blockbuster to its respiratory franchise.

On the mega-cap front, Alibaba (BABA) is getting attention after reports surfaced that it plans to order Huawei's new AI chips following successful testing. This partnership could help Alibaba reduce reliance on foreign semiconductor suppliers while supporting China's domestic chip industry. The move has implications for how Chinese tech companies navigate the current geopolitical landscape.

Rivian (RIVN) is showing some life after news that its software joint venture with Volkswagen hit a critical milestone. The partnership brings Rivian closer to monetizing its technology beyond its own vehicle sales, which could help justify its valuation as production ramps remain challenging. Volkswagen (VWAGY) benefits too, gaining access to the software architecture it desperately needs to compete with Tesla and Chinese EV makers.

Tiny "$3 AI Wonder Stock" Could Make You Richer [ad]

🔍 Today's Watchlist

1. Healthcare M&A speculation following recent biotech approvals
2. AI chip competition heating up between Nvidia and Huawei
3. Treasury yield curve dynamics and Fed rate expectations
4. Electric vehicle software partnerships and tech valuations
5. SoftBank's aggressive AI investment strategy and leverage

🎯 The Morning Playbook

Today's session is shaping up as a classic end-of-week positioning trade, with yields rising, the dollar strengthening, and growth stocks facing headwinds. But the healthcare wins remind us that company-specific catalysts still matter, even when the macro backdrop turns choppy. If you're hunting for opportunities, look at sectors where fundamentals are improving regardless of rate movements.

The AI chip narrative is evolving rapidly. Huawei's success in attracting Chinese tech giants shows that Nvidia's dominance has geographic limits, and companies like Alibaba are willing to bet on domestic alternatives. This bifurcation of the global tech ecosystem is a theme that will play out for years, creating winners and losers on both sides of the Pacific.

As we close out the week, keep your eyes on Treasury yields and the dollar. If yields keep climbing, growth stocks will struggle, but quality healthcare and value plays could find footing. Sometimes the best move on a red futures morning is to identify what's working rather than fighting the tape. Stay selective, stay sharp, and remember that volatility creates opportunity for those who keep their heads while others lose theirs.

Did Trump just Turbocharge the "29% Account"? [ad]